Biotech Top 50 Companies Announce Major Regulatory and Clinical Milestones in IPO Filing
PHASE Scientific
Developer of Liquid Biopsy Diagnostic Technology
Xbiome
AI Drug Developer for Gut Microbiota
1
PHASE Scientific Exclusive Agent FebriDx® Receives FDA CLIA Waiver in the U.S.; Exclusive Distributor in the U.S. Ready to Accelerate the Implementation of Point-of-Care Testing
2
AIMLAM - Lipomannan (LAM) Detection Kit (Chemiluminescence Method) Successfully Obtains National Class III Medical Device Registration Certificate
3
FMT Reverses Immune Resistance in Gastrointestinal Tumors: Xbiome and Beijing Cancer Hospital Collaborate on Study Published in BMJ Journal
PART.1
PHASE Scientific
March 27,Top 50 Pioneering Enterprises in Biotechnology Innovation for the Fourth Year ——PHASE Scientific Announces FDA CLIA Waiver for FebriDx®Previously, PHASE Scientific had signed a distribution agreement with Lumos Diagnostics to become the exclusive distributor of FebriDx® in the United States. This CLIA waiver represents another significant regulatory milestone for the product following its 510(k) clearance (Number K260787).
PHASE Scientific is a rapidly growing biotechnology company dedicated to bringing people a new state of health through innovative diagnostic and medical solutions. The company's operations cover the United States, mainland China, and the Hong Kong Special Administrative Region, providing innovative diagnostic tools and services for cancer and infectious diseases using proprietary technology to help achieve more precise disease detection, diagnosis, and management.
PHASE Scientific's products and services have received certifications from the U.S. Food and Drug Administration (FDA), EU CE certification, and multiple national regulatory authorities, cumulatively providing over 100 million testing products and services to more than 30 countries worldwide. PHASE Scientific completed a $34 million Series A financing round in 2025, marking the largest Series A financing in Asia's molecular diagnostics technology sector since 2019.
PART.2
Redbiel
Top 50 Pioneering Enterprises in Biotechnology Innovation for the Sixth Year ——Redbiel's Innovative Tuberculosis Diagnostic Product AIMLAM – Lipopolysaccharide Arabino Mannan (LAM) Detection Kit (Chemiluminescence Method) Successfully Obtains Class III Medical Device Registration Certificate Issued by the National Medical Products Administration。
As the first IVD registered product for auxiliary diagnosis of active tuberculosis (ATB) using urine as a sample, Reed Bell's AIMLAM offers convenient, non-invasive, and painless sampling. Utilizing a chemiluminescence platform, it combines high sensitivity with high specificity, providing rapid detection and stable results. It overcomes the limitations of traditional sputum smear and sputum culture methods, which suffer from low sensitivity, long testing times, and reliance on the quality of sputum samples, making it suitable for clinical auxiliary diagnosis of both pulmonary and extrapulmonary tuberculosis.
PART.3
Xbiome
Top 50 Leading Enterprises in Biotechnology Innovation, 8th Edition ——Xbiome and the joint research team with Professor Shen Lin from Peking University Cancer Hospital (hereinafter referred to as "PKUCC") have reported another success.
The research成果 "Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study" (肠菌移植联合抗PD-1疗法治疗难治性微卫星稳定型胃癌的I期可行性与安全性研究) has been officially published in the Journal for ImmunoTherapy of Cancer (JITC, JCR Q1, CAS Q1, Impact Factor 10.6), a prestigious journal under BMJ Journals.
Xbiome owns a leading AI microbiome research and industrial transformation platform, strategically focusing on three areas: FMT, drug discovery, and probiotics. In drug discovery, the team has completed its layout in fields such as oncology, digestive diseases, immune-related diseases, and urological diseases. Four pipelines have entered clinical stages, with two of them advancing to phase II clinical trials.
About the Top 50 Biotech Innovation Awards
The Top 50 Biotechnology Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area selection, hosted by the Zhongchuang Industry Research Institute and organized by Guangdong Medical Valley, has been successfully held for eight consecutive years. As the largest and most dynamic multilateral resource exchange and sharing industrial innovation ecosystem in the Greater Bay Area's biopharmaceuticals industry, it aims to discover China's future biotech unicorns. The platform provides biotech enterprises with a comprehensive industrial resource network that connects companies, academia, and government entities, accelerating the development of China’s biopharmaceuticals industry through industrial collaboration and resource integration.
For industry communication groups, cooperation, contributions, etc.
Please scan the QR code to add
